Brokers Provide Earnings Predictions for IQVIA Holdings Inc.

IQVIA Holdings Inc. (NYSE:IQV) recently saw an increase in earnings per share (EPS) estimates for the first quarter of 2025, according to research analysts at Zacks Research. In a report released on February 25th, analyst R. Department raised the projected earnings to $2.38 per share, up from the previous estimate of $2.34. For the current fiscal year, the consensus estimate for IQVIA's earnings stands at $10.84 per share.

Zacks Research has also provided estimates for future quarters, highlighting expectations for the second quarter of 2025 at $2.56 EPS, the third quarter of 2025 at $2.81 EPS, and an annual estimate for the fiscal year 2025 of $10.79 EPS. Looking further ahead, estimates for Q1 2026 are expected to be $2.57 EPS, with subsequent quarters projecting $2.87 for Q2 2026, $3.29 for Q4 2026, and annual earnings for FY2026 at $11.99 EPS. By FY2027, earnings are anticipated to reach $13.66 EPS.

In its most recent financial report for Q4, IQVIA announced earnings of $2.90 EPS on February 6th, which fell short of analysts' expectations of $3.11 by $0.21. The company's return on equity was reported at 28.81%, with a net margin of 8.91%.

Other financial institutions have recently adjusted their price targets for IQVIA. Bank of America lowered its price target from $255.00 to $235.00 while maintaining a "buy" rating. Similarly, Deutsche Bank Aktiengesellschaft reduced its target price from $270.00 to $265.00, also affirming a "buy" rating. Leerink Partners continued to rate IQVIA as "outperform" but adjusted its target price down to $248.00 from $260.00. Truist Financial has reiterated a "buy" rating, increasing its target price to $263.00 from $261.00. According to reports, the overall consensus shows that the stock has received "Moderate Buy" ratings, with a consensus target price of $251.22 based on MarketBeat data.

IQVIA's Stock Performance

The stock of IQVIA was trading at $186.40 on the morning of Friday, February 25th, down by 2.4%. Over the last year, the stock reached a low of $184.66 and a high of $261.73. With a market capitalization of approximately $32.82 billion, IQVIA holds a price-to-earnings (P/E) ratio of 24.85, a price-to-earnings growth (PEG) ratio of 1.99, and a beta of 1.48. The company reports a current ratio and quick ratio both at 0.84 and maintains a debt-to-equity ratio of 2.12. IQVIA's 50-day moving average price is $199.30, while the 200-day moving average stands at $215.26.

Insider Trading Activity

In a recent development, Director John G. Danhakl acquired 1,275 shares of IQVIA on December 3rd at an average price of $200.58 per share, amounting to a total investment of $255,739.50. This purchase indicates an increase in the director's stake in the company. Following the transaction, Danhakl now owns 1,275 shares valued at approximately $255,739.50, reflecting a significant investment by an insider.

Investors' Interest in IQVIA

Several institutional investors have shown interest in IQVIA, with some recently purchasing shares. Capital Performance Advisors LLP entered into a new investment in IQVIA worth $27,000 during the third quarter. Avior Wealth Management LLC increased its holdings by 117.6%, now owning 161 shares valued at $38,000 after acquiring additional shares. Other firms, such as GKV Capital Management and Lee Danner & Bass, also made investments, indicating strong institutional support. Currently, institutional investors own approximately 89.62% of IQVIA's stock.

About IQVIA

IQVIA Holdings Inc. specializes in providing advanced analytics, technology solutions, and clinical research services to the life sciences sector across the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three primary segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Earnings, Stock, Predictions